Using an extensive synthetic compound library, the companies plan to develop AI-based synthetic drugs. Credit: Enamine.

AI drug discovery company Syntekabio has partnered with Ukraine-based global compound supplier Enamine for supply, synthesis of compounds and synthetic drug development.

Under the Memorandum of Understanding (MOU) signed by the companies, the alliance will leverage an extensive synthetic compound library provided by Enamine to support drug candidate discovery services through Syntekabio’s AI platform, DeepMatcher.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Syntekabio and Enamine will work at the AI Bio Supercomputer Center (ABS Center) in Daejeon, South Korea.

Their aim is to derive optimised lead compounds for drug development, combining Syntekabio’s AI capabilities with Enamine’s chemical synthesis and preclinical biology services.

The companies also plan joint marketing to accelerate their expansion in the global market for AI-driven drug discovery services.

Enamine is growing its global presence with branches in the US, Germany and Poland.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Its comprehensive services include in vitro efficacy verification, binding assays and ADMET [absorption, distribution, metabolism, excretion and toxicity] screening.

Enamine will apply its knowledge in chemical, custom synthesis and preclinical biology services to work with Syntekabio on therapeutic optimisation and extraction of lead compounds utilising the AI-based molecular design technology of Syntekabio.

Syntekabio is also conducting bio-drug research using its NEO-ARS and Ab-ARS services.

NEO-ARS is a personal and shared neoantigen prediction service. Ab-ARS focuses on new antibody discovery and optimisation research.

Enamine business development director Dr Iaroslava Kos stated: “We are excited to collaborate with Syntekabio to integrate our extensive compound library with their advanced AI platform.

“This partnership aims to accelerate the discovery of optimised lead compounds, enhancing the efficiency and effectiveness of drug development. By combining our strengths, we look forward to making significant advancements in the field of synthetic drug development.”